Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Achieving the golden Grail in solid tumor treatment

Project description

Macrophages as a Trojan Horse against tumours

Macrophages are key players of the immune system and function by phagocytosing pathogens and foreign substances. They also have the ability to infiltrate tumours and promote or suppress tumour growth, making them a promising target for immunotherapy. The ERC-funded AGAINST project capitalises on the great promise of macrophage therapy and the ability of macrophages to uptake anti-cancer drugs and transfer them to solid tumours. This approach not only induces cancer cell death but also generates immunological memory upon tumour rechallenge. In this project, researchers will investigate the underlying mechanisms of this resistance as well as immune responses in mouse models. Project results have the potential to advance this technology for clinical application.

Objective

Macrophage therapy is promising for solid tumor treatment as these cells are continuously recruited into the tumor mass, even the most hypoxic regions. Our pioneering research demonstrated that macrophages are able to take up ferritins loaded with anti-cancer drugs, creating Macrophage-Drug Conjugates (MDCs), and transfer these to cancer cells and kill them, a phenomenon we named TRAIN. In my ongoing ERC Starting Grant PROJECT McHAP, we have proven that MDCs can be sucessfully used not only to treat solid tumors but also to induce subsequent resistance to the tumor re-challenge. Acquisition of resistance to tumor development after specific therapy is a 'Golden Grail' in oncology.
Now we aim to turn the MDC technology into a commercial and social value proposition by confirming mechanisms of tumor-resistance in tumor-bearing mice and identify immune response. This is crucial to raise interest of and establish a co-development (or licensing) deal with big pharmas to realize commercialization and clinical uptake of our IP-protected MDC technology. During the ERC PoC project, we will perform high-dimensional spectral flow cytometry, spatial transcriptomics and single-cell transcriptomics of the tumor before and after MDC treatment to identify mechanisms of tumor-resistance and optimize our business case. This project will thus provide proof of concept for the immune activation after the MDC treatment and thus establish the viability, feasibility, commercialization and overall direction for our innovative MDC technology. This project will substantially contribute to bring our MDC technology to the market and clinical practice.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-POC2

See all projects funded under this call

Host institution

SZKOLA GLOWNA GOSPODARSTWA WIEJSKIEGO
Net EU contribution
€ 150 000,00
Address
UL. NOWOURSYNOWSKA 166
02 787 WARSZAWA
Poland
Region
Makroregion województwo mazowieckie Warszawski stołeczny Miasto Warszawa
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)